Real-World Retrospective Safety Analysis of OnabotulinumtoxinA for the Treatment of Patients with Chronic Migraine and Concomitant Therapeutic Indications
TEAEs associated with onabotulinumtoxinA treatment in adults with CM and ≥ 1 coexisting disease within 3 months were generally consistent with the known safety profiles for the individual onabotulinumtoxinA indications. There were no new safety signals observed for up to 6 months after multi-indication treatment.
Authors
- Kenneth Martinez (ORCID: https://orcid.org/0000-0001-7651-8023)
- Simona Battucci
- I. Yushmanova
- Grace Forde
- Marc A. Schwartz (ORCID: https://orcid.org/0000-0003-3869-0150)
- Christopher Rhyne (ORCID: https://orcid.org/0000-0002-4540-4485)
- Kim Becker Ifantides
- Andrew M. Blumenfeld
- Ritu Singh
- Atul Patel
Institutions
- AbbVie (United States) (US)
- Pain and Headache Center (US)
- Diamond Headache Clinic (US)
- Soka University of America (US)
Publication Details
- Journal
- Pain and Therapy
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1007/s40122-026-00816-z
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00